Download PDF
Semin Thromb Hemost 2024; 50(06): 835-841
DOI: 10.1055/s-0043-1776004
Review Article

Trends (2020–2022) toward Reduced Prevalence of Postcoronavirus Disease Syndrome and Improved Quality of Life for Hospitalized Coronavirus Disease 2019 Patients with Severe Infection and Venous Thromboembolism

Antonio Bozzani
1   Vascular and Endovascular Surgery Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Vittorio Arici
1   Vascular and Endovascular Surgery Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Guido Tavazzi
2   Anesthesiology and Intensive Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
3   Department of Medical, Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, Italy
,
Franco Ragni
1   Vascular and Endovascular Surgery Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Francesco Mojoli
2   Anesthesiology and Intensive Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
3   Department of Medical, Surgical, Diagnostic and Pediatric Science, University of Pavia, Pavia, Italy
,
Elena Cavallini
4   Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
,
Floris van Vugt
5   Department of Psychology, University of Montreal, Centre-ville Montréal, Canada
,
Sara Cutti
6   Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Silvia Figini
7   Department of Political and Social Sciences, University of Pavia, Pavia, Italy
,
Alessandro Venturi
8   Presidenza, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
,
Antonio V. Sterpetti
9   Department of Surgery, Università La Sapienza, Roma, Italy
,
Eloisa Arbustini
10   Transplant Research Area and Centre for Inherited Cardiovascular Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
› Author Affiliations
› Further Information
    Permissions and Reprints

Abstract

The coronavirus disease 2019 (COVID-19) pandemic seems to be at its end. During the first outbreak, alfa was the dominant variant, and in the two following years, delta was the dominant variant. Questions remain about the prevalence and severity of post-COVID syndrome (PCS). We compared the medium-term outcomes of a selected group of patients considered at high risk for PCS: hospitalized patients with severe COVID-19 infection who presented clinical evidence of the acute onset of venous thromboembolism. Weighted Cox regression was used to estimate the adjusted hazard ratios for the risk of early and medium-term complications and quality of life (QoL) in COVID-19 patients developing acute venous thrombo-embolism according to the period of admission to the hospital. The primary outcome was the modification of QoL at a median follow-up of 24 months in patients hospitalized for COVID-19. The secondary outcome was the modification of QoL related to COVID-19 severity. The absolute risk of mortality for hospitalized COVID-19 patients was higher during the first outbreak (risk difference, 19% [95% confidence interval [CI], 16–22%]). Patients with acute onset of thromboembolism during the first outbreak had increased mortality, hospital stay, and need for intensive care unit treatment (p < 0.01). In patients who suffered from severe COVID-19 infection and thromboembolism in the following 2 years, symptoms during follow-up were less common and milder (risk difference 45% [95% CI, 40–52%]. In total, 19 patients were alive at 24 months follow-up: 12 patients (63%) reported important physical symptoms and 10 patients (52%) relevant emotional/mental symptoms. All patients reported reduced QoL in comparison with the preinfection time; in 15 patients (79%), the reduced QoL limited significantly their social and work activities. All patients reported permanent worsening of QoL after discharge from the hospital. Comparing the three different February to April interval years (2020, 2021, and 2022), patients reported a somewhat worse perception of health condition in comparison with the preinfection time, respectively, in 100, 79, and 56% respectively. The findings of our study show reduced prevalence and severity of PCS in the last 2 years. Less virulent variants, herd immunity, and vaccination may played a significant role.

Keywords

COVID-19 - quality of life - thrombosis - survival - median follow-up

Data Availability

Data are available on request.




Publication History

Article published online:
13 October 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Wulf Hanson S, Abbafati C, Aerts JG. et al; Global Burden of Disease Long COVID Collaborators. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 2022; 328 (16) 1604-1615
    Google Scholar
  • 2 Di Toro A, Bozzani A, Tavazzi G. et al. Long COVID: long-term effects?. Eur Heart J Suppl 2021; 23 (Suppl E): E1-E5
    CrossrefPubMedGoogle Scholar
  • 3 Thompson EJ, Williams DM, Walker AJ. et al; OpenSAFELY Collaborative. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. Nat Commun 2022; 13 (01) 3528
    CrossrefPubMedGoogle Scholar
  • 4 Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat Med 2022; 28 (03) 583-590
    CrossrefPubMedGoogle Scholar
  • 5 Nalbandian A, Sehgal K, Gupta A. et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27 (04) 601-615
    CrossrefPubMedGoogle Scholar
  • 6 Heesakkers H, van der Hoeven JG, Corsten S. et al. Clinical outcomes among patients with 1-year survival following intensive care unit treatment for COVID-19. JAMA 2022; 327 (06) 559-565
    CrossrefPubMedGoogle Scholar
  • 7 Morin L, Savale L, Pham T. et al; Writing Committee for the COMEBAC Study Group. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA 2021; 325 (15) 1525-1534
    CrossrefPubMedGoogle Scholar
  • 8 Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol 2023; 21 (03) 133-146
    CrossrefPubMedGoogle Scholar
  • 9 Gandhi RT, Lynch JB, Del Rio C. Mild or moderate COVID-19. N Engl J Med 2020; 383 (18) 1757-1766
    CrossrefPubMedGoogle Scholar
  • 10 Bikdeli B, Madhavan MV, Jimenez D. et al; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol 2020; 75 (23) 2950-2973
    CrossrefPubMedGoogle Scholar
  • 11 Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res 2001; 10 (05) 405-413 , discussion 415–420
    CrossrefPubMedGoogle Scholar
  • 12 Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med 2022; 28 (11) 2398-2405
    CrossrefPubMedGoogle Scholar
  • 13 Bozzani A, Arici V, Tavazzi G. et al. Acute arterial and deep venous thromboembolism in COVID-19 patients: risk factors and personalized therapy. Surgery 2020; 168 (06) 987-992
    CrossrefPubMedGoogle Scholar
  • 14 Bozzani A, Arici V, Tavazzi G. et al. Acute thrombosis of lower limbs arteries in the acute phase and after recovery from COVID19. Ann Surg 2021; 273 (04) e159-e160
    CrossrefPubMedGoogle Scholar
  • 15 Azzolini E, Levi R, Sarti R. et al. Association between BNT162b2 vaccination and long COVID after infections not requiring hospitalization in health care workers. JAMA 2022; 328 (07) 676-678
    CrossrefPubMedGoogle Scholar
  • 16 Willan J, Agarwal G, Bienz N. Mortality and burden of post-COVID-19 syndrome have reduced with time across SARS-CoV-2 variants in haematology patients. Br J Haematol 2023; 201 (04) 640-644
    CrossrefPubMedGoogle Scholar
  • 17 Houston A, Tovey C, Rogers-Smith K. et al. Changing characteristics of post-COVID-19 syndrome: cross-sectional findings from 458 consultations using the Stanford Hall remote rehabilitation assessment tool. BMJ Mil Health 2023; e002248 (e-pub ahead of print). DOI: 10.1136/military-2022-002248.
    CrossrefPubMedGoogle Scholar
  • 18 Bertuccio P, Perotti P, Mosconi G. et al. The effect of COVID-19 pandemic on overall and cause-specific mortality in Pavia, Northern Italy: updated estimates for the year 2021. Int J Environ Res Public Health 2023; 20 (08) 5529
    CrossrefPubMedGoogle Scholar
  • 19 Greene SK, Levin-Rector A, McGibbon E. et al. Reduced COVID-19 hospitalizations among New York City residents following age-based SARS-CoV-2 vaccine eligibility: evidence from a regression discontinuity design. Vaccine X 2022; 10: 100134
    CrossrefPubMedGoogle Scholar
  • 20 COVID Surg Collaborative. GlobalSurg Collaborative. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international perspective cohort study. Br J Surg 2021; 108 (09) 1056-1063
    CrossrefPubMedGoogle Scholar
  • 21 Rovida F, Esposito GL, Rissone M. et al. Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy. Int J Infect Dis 2022; 122: 420-426
    CrossrefPubMedGoogle Scholar
  • 22 World Health Organization. Statement on the fifteenth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic. www/who/int. covid-19. May 4th, 2023
    PubMedGoogle Scholar
  • 23 Harris E. Updated WHO guidance for prioritizing COVID-19 vaccines. JAMA 2023; 329 (17) 1444
    CrossrefPubMedGoogle Scholar
  • 24 Tran V-T, Riveros C, Clepier B. et al. Development and validation of the long coronavirus disease (COVID) symptom and impact tools: a set of patient-reported instruments constructed from patients' lived experience. Clin Infect Dis 2022; 74 (02) 278-287
    CrossrefPubMedGoogle Scholar